Today: 8 June 2026
Browse Category

NASDAQ:MRNA 13 January 2026 - 11 May 2026

Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna’s early-stage hantavirus vaccine research drew renewed attention after a deadly Andes virus outbreak on the MV Hondius cruise ship, with six confirmed cases and three deaths reported. Moderna shares closed up nearly 12% Friday. WHO and ECDC rated the broader public risk as low, but recommended a 42-day quarantine for passengers. No approved vaccine or treatment for Andes virus exists, according to the CDC.
11 May 2026
··
Moderna Stock Surges on Hantavirus Vaccine Research as MRNA Investors Eye Flu and Cancer Pipeline

Moderna Stock Surges on Hantavirus Vaccine Research as MRNA Investors Eye Flu and Cancer Pipeline

Moderna confirmed early-stage research on hantavirus vaccines with U.S. Army and Korea University partners, following a deadly outbreak on the MV Hondius cruise ship. Eight cases, including three deaths, have been reported; six cases are confirmed. Moderna shares rose 11.9% to $54.35. Spain and several EU countries are preparing evacuations as the ship nears Tenerife.
9 May 2026
··
Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus

Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus

Moderna shares rose about 10% Friday after the company announced research into vaccines for hantaviruses amid a deadly Andes virus outbreak linked to the MV Hondius cruise ship. WHO reported eight cases and three deaths, with five confirmed as hantavirus. Moderna’s vaccine program is in early stages, with commercial availability still years away. The U.S. is arranging a repatriation flight for 17 Americans from the ship.
8 May 2026
·
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna’s first-quarter revenue jumped to $389 million, driven by international Covid vaccine sales, while U.S. revenue fell to $78 million. The company posted a net loss of $1.34 billion after a $900 million patent settlement charge. Shares fell 2.7% in early trading. Moderna kept its 2026 growth target and expects FDA action on its flu vaccine by August 5, 2026.
1 May 2026
·
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
15 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares fell 6.09% to $48.71 Friday after CEO Stéphane Bancel said the company will scale back new late-stage vaccine trials, citing U.S. resistance and policy delays. The drop followed a midweek rally on positive cancer vaccine data with Merck. Investors await Moderna’s Feb. 13 results for further updates. U.S. markets are closed until Monday.
24 January 2026
···
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·····
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna shares jumped 4.2% to $51.87 in after-hours trading Thursday after CEO Stephane Bancel said the company will halt new late-stage vaccine trials, citing resistance from U.S. officials and an unreliable U.S. market. The move follows weak COVID vaccine demand and comes as Moderna and Merck reported their experimental cancer vaccine cut melanoma recurrence or death by 49% over five years in a mid-stage study.
23 January 2026
··
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares rose 7.7% to $53.65 Thursday after five-year data showed its personalized cancer vaccine with Merck’s Keytruda cut melanoma recurrence or death risk by 49%. The phase 2b trial enrolled 157 patients and met its primary endpoint. Investors await phase 3 trial updates and Moderna’s Feb. 13 results call. The stock had jumped 15.8% Wednesday on the initial data release.
22 January 2026
··
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
··
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·····
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck shares traded near $108.82 Tuesday after Merck and Moderna reported their personalized melanoma vaccine with Keytruda cut recurrence or death risk by 49% over five years in a phase 2b trial. The stock showed little change following the update. More data will be presented at a future medical meeting. Investors await Merck’s Feb. 3 earnings call for further details on its oncology portfolio.
20 January 2026
····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next

Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next

Moderna shares fell about 1% to $39.20 premarket Wednesday after a 17% surge the day before. The company raised its 2025 revenue estimate to $1.9 billion and cut its operating-expense outlook by $200 million. Moderna expects several vaccine approvals and trial updates in 2026, with Q4 results due February 13. U.S. retail vaccination rates dropped 26% in 2025, less than expected.
14 January 2026
·
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna shares jumped 11.7% to $37.81 after the company raised its 2025 sales outlook to about $1.9 billion and cut its operating expense forecast by $200 million. The company reiterated its 2026 growth target and said it does not expect flu or COVID-flu shots to be approved for the 2026 season. Investors await Feb. 13 results and early-2026 cancer vaccine data with Merck.
13 January 2026
··
1 2 3

Stock Market Today

  • Inflation Risks Rise with Pacific Climate Shock: Protect Your Portfolio
    June 8, 2026, 3:50 PM EDT. A brewing climate shock in the Pacific Ocean could trigger a surge in global commodity prices, raising inflation risks worldwide. This development threatens to erode purchasing power for investors. Experts warn that traditional portfolios may not be prepared for such a spike, urging a strategic shift towards inflation-protected assets. Diversifying with commodities or inflation-linked securities could help mitigate the impact. Investors should monitor climate and market signals closely to safeguard wealth against this emerging inflation threat.

Latest articles

Tesla Stock Bounces Over $400 After China Sales Beat—But There’s a Caveat

Tesla Stock Bounces Over $400 After China Sales Beat—But There’s a Caveat

8 June 2026
Tesla shares soared over 5% to $411.66 after a China sales report showed May retail sales up 22.5%, ending a two-month decline, and J.P. Morgan upgraded the stock, citing rising value from autonomy and software; the rally outpaced the Nasdaq as investors bet on Tesla’s China resilience and technology story despite a lofty price-to-earnings ratio of about 378.
Ondas Stock Comes Back Into the Spotlight After 13% Drop; Drone Trade Faces Fresh Challenge

Ondas Stock Comes Back Into the Spotlight After 13% Drop; Drone Trade Faces Fresh Challenge

8 June 2026
Ondas shares slipped 0.5% to $10.38 as investors weighed a new $4.8M U.S. Navy-linked balloon contract and $110M in Q2 orders against high short interest (31.33% of float), rising operating losses, and fresh stock-supply concerns after a June 3 filing revealed more Omnisys-related shares could hit the market, raising dilution risks despite surging revenue and backlog.
Archer Aviation Shares Bounce Back, FAA Timeline and Cash Burn in Focus

Archer Aviation Shares Bounce Back, FAA Timeline and Cash Burn in Focus

8 June 2026
Archer Aviation shares jumped 4.2% to $5.77 after last week’s 13.2% drop, as investors rotated back into growth and air-taxi stocks; the move follows Archer’s milestone as the first eVTOL developer to close Phase 3 of FAA certification, but heavy losses and high cash burn keep the stock highly sensitive to regulatory and financial risks.
Galaxy Digital spikes 24% as investors look at AI data center plans

Galaxy Digital spikes 24% as investors look at AI data center plans

8 June 2026
Galaxy Digital shares soared 23.6% to $31.07 after CEO Mike Novogratz said its West Texas AI data center—half of which is already leased—now represents more than half the company’s value, shifting focus from crypto to AI infrastructure; the stock’s surge outpaced bitcoin’s 2.7% rise as investors repriced Galaxy’s data-center business amid execution risks and strong analyst buy ratings.
Go toTop